These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33363383)

  • 1. PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Sun C; Zhou F; Li X; Zhao C; Li W; Li J; Xiong A; Yu J; Gao G; Wang Q; Wu F; Zhou C
    Onco Targets Ther; 2020; 13():12777-12786. PubMed ID: 33363383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of PD-1 Inhibitors Combined with Anti-Angiogenic Therapy in Driver Gene Mutation Negative Non-Small-Cell Lung Cancer with Brain Metastases.
    Song JQ; Wang X; Zeng ZM; Liang PA; Zhong CY; Liu AW
    Discov Med; 2023 Jun; 35(176):321-331. PubMed ID: 37272099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.
    Chen M; Wei L; Wang Q; Xie J; Xu K; Lv T; Song Y; Zhan P
    Transl Lung Cancer Res; 2023 Apr; 12(4):689-706. PubMed ID: 37197616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence.
    Huang L; Chen S; Liu H; Meng L; Liu C; Wu X; Wang Y; Luo S; Tu H; Wang C; Zhang M; Gong X
    Cancer Med; 2024 Apr; 13(7):e7125. PubMed ID: 38613182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents.
    Yang D; Munai E; Zeng S; Tao D; Yuan Z; Du L; Zhou W; Wu Y; Zhu XD
    Cancer Immunol Immunother; 2024 Sep; 73(11):226. PubMed ID: 39237636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
    Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
    Front Oncol; 2021; 11():690093. PubMed ID: 34150659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lau SCM; Poletes C; Le LW; Mackay KM; Fares AF; Bradbury PA; Shepherd FA; Tsao MS; Leighl NB; Liu G; Shultz D; Sacher AG
    Lung Cancer; 2021 Jun; 156():76-81. PubMed ID: 33932863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
    Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
    Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
    Gao G; Jia K; Zhao S; Li X; Zhao C; Jiang T; Su C; Ren S; Zhou F; Zhou C
    Transl Lung Cancer Res; 2019 Dec; 8(6):920-928. PubMed ID: 32010570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung cancer: a multicenter retrospective study.
    Ma J; Bi J; Tuo X; Pi G; Li Y; Li Y; Zeng F; Gong H; Hu D; Han G
    J Thorac Dis; 2022 Feb; 14(2):455-463. PubMed ID: 35280489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
    Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study.
    Bodensohn R; Kolorz A; Reis J; Werner S; Forbrig R; Garny S; Taugner J; de Colle C; Belka C; Manapov F; von Baumgarten L; Niyazi M
    Transl Lung Cancer Res; 2024 Jul; 13(7):1635-1648. PubMed ID: 39118877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis.
    Li S; Zhang H; Liu T; Chen J; Dang J
    Front Oncol; 2021; 11():702924. PubMed ID: 34249764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
    Yang K; Li J; Bai C; Sun Z; Zhao L
    Front Oncol; 2020; 10():1098. PubMed ID: 32733805
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.